| Christopher Roenfeldt |
Christopher Roenfeldt is currently the Chief Operating Officer at Forte Biosciences, Inc. He previously worked as a Manager-Alliance & Program at Halozyme, Inc. He completed his undergraduate degree at The University of Colorado. |
| Paul A. Wagner |
Paul A. Wagner is the founder and currently serves as the Chairman, President & Chief Executive Officer of Forte Biosciences, Inc., a company he founded in 2017. He previously held the position of Chairman, President & Chief Executive Officer at Tocagen, Inc. Dr. Wagner also has experience as the Associate Director & Head-Development Licensing at PDL BioPharma, Inc. from 2005 to 2006, Director & Portfolio Manager at Allianz Global Investors U.S. LLC from 2013 to 2014, Portfolio Manager at RCM Capital Management LLC from 2006 to 2013, and Research Analyst at Lehman Brothers Asset Management LLC from 1999 to 2005. Additionally, he served as the Chief Financial Officer of Pelican Inc. from 2014 to 2017 and as the Head of Corporate Strategy & Development at CANbridge Life Sciences Ltd. Dr. Wagner holds a doctorate degree from the California Institute of Technology, which he received in 1999, and an undergraduate degree from the University of Wisconsin. |
| Steven J. Ruhl |
Steven J. Ruhl is an Independent Director at Scripps Safe, Inc. and the Chief Technical Officer at Forte Biosciences, Inc. He previously worked as an Executive Director-Commercial Drug Product at Amgen, Inc., Director-Process Development at Generation Technologies, Inc., Vice President-Manufacturing at CancerVax Corp., and Vice President-Manufacturing at Avenir Wellness Solutions, Inc. He obtained his undergraduate degree from Brigham Young University. |
| Anthony A. Riley |
Anthony A. Riley's current job(s) include being a Partner at The CFO Network LLC since 2002 and serving as the Chief Financial Officer at Forte Biosciences, Inc. since 2020. Formerly, Mr. Riley worked as the Vice President-Finance & Accounting at Avanex Corp. from 2005 to 2007, as the Controller at Kosan Biosciences, Inc. from 2000 to 2001, and as the Chief Financial Officer at Krystal Biotech, Inc. from 2017 to 2020. Mr. Riley completed his undergraduate degree at the University of Bristol and holds an MBA from The University of Chicago Booth School of Business. |
| Hubert C. Chen |
Presently, Hubert C. Chen holds the position of President & Chief Scientific Officer at Forte Biosciences, Inc.
In the past he held the position of Chief Medical Officer of Metacrine, Inc., Associate Director-Medical Sciences at Amgen, Inc., Vice President-Clinical Development at Aileron Therapeutics, Inc., Vice President-Translational Medicine at Regulus Therapeutics, Inc., Senior Director-Clinical Research at Amylin Pharmaceuticals, Inc., Chief Medical & Scientific Officer at Pfenex, Inc., Assistant Clinical Professor at The University of California, San Francisco and Staff Research Investigator at The J. David Gladstone Institutes.
Dr. Chen received a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Stanford University. |
| Lawrence F. Eichenfield |
Lawrence F. Eichenfield is the founder of Pediatric Dermatology Research Alliance. He currently holds the position of Director at the American Dermatological Association, Inc. Additionally, he serves as an Independent Director at both Verrica Pharmaceuticals, Inc. and Forte Biosciences, Inc. Dr. Eichenfield previously worked as a Professor & Vice Chairman-Dermatology Department at UC San Diego School of Medicine and as President & Director at the American Acne & Rosacea Society. He also served as a Director at Forte Biosciences, Inc. and as a Director at the American Academy of Dermatology from 2005 to 2009. Furthermore, Dr. Eichenfield was the President of the Society For Pediatric Dermatology from 2002 to 2003. He obtained his undergraduate degree from the Icahn School of Medicine at Mount Sinai. |
| Scott Brun |
Scott Brun is the founder of Gold Mast Consulting, LLC, which was founded in 2019. He is currently the President of Gold Mast Consulting, LLC. Dr. Brun's current jobs include being a Director at Axial Therapeutics, Inc. since 2020, an Independent Director at Cabaletta Bio, Inc. since 2021, an Independent Director at Forte Biosciences, Inc. since 2022, a Director at Trishula Therapeutics, Inc., and an Independent Director at Jasper Therapeutics, Inc. starting in 2023. He is also a Venture Partner at Abingworth Management, Inc. and serves on the Advisory Board of Accelerator Services Corp. Dr. Brun's former jobs include being the Head of Clinical Development at Abbott Laboratories and the Vice President & Head of AbbVie Ventures at AbbVie, Inc. from 2016 to 2019. Dr. Brun obtained a doctorate degree from The Johns Hopkins University School of Medicine in 1993 and an undergraduate degree from the University of Illinois At Urbana–Champaign in 1989. |
| Donald A. Williams |
Donald A. Williams is currently the Chairman at Palisade Bio, Inc. since 2024. He is also the Director at ImpediMed, Inc. since 2017, the Independent Director at Akari Therapeutics Plc since 2016, the Director at Leading Biosciences, Inc. since 2019, and the Independent Director at Forte Biosciences, Inc. since 2020. Previously, Mr. Williams served as the Chairman & President at San Diego Venture Group from 2001 to 2014. He was also the Non-Executive Chairman at ImpediMed Ltd. from 2017 to 2023, the Independent Director at Alphatec Holdings, Inc. from 2015 to 2021, and the Director at Alphatec Spine, Inc. from 2015 to 2021. Additionally, he held the position of Independent Director at Adhera Therapeutics, Inc. from 2014 to 2019 and Director at Proove Biosciences, Inc. from 2015 to 2017. Mr. Williams has a background in business and finance, having worked as the Managing Partner at Grant Thornton LLP from 2007 to 2014. He also held positions at Grant Thornton International Ltd. and Ernst & Young LLP (United Kingdom). Furthermore, he served as a Trustee at CONNECT. Mr. Williams completed his undergraduate degree at Southern Illinois University. |
| Steven Andrew Kornfeld |
Steven Andrew Kornfeld is currently the Director at Lark Technologies, Inc., the Independent Director at Forte Biosciences, Inc., the Co-Managing Partner at Castle Peak Partners LLC, and the Chief Strategy Officer at Joyous, Inc. Previously, he worked as the Vice President & Portfolio Manager at Franklin Resources, Inc., the Co-Manager at Franklin Biotechnology Discovery Fund, and the Vice President & Research Analyst at Franklin Advisers, Inc. He obtained his undergraduate degree from The Wharton School of the University of Pennsylvania and his MBA from Kellogg School of Management. |
| David W. Gryska |
David W. Gryska is currently an Independent Director at Mind Medicine (MindMed), Inc. and Forte Biosciences, Inc. He previously served as the President, CEO, COO & Director at Myrexis, Inc. in 2012. From 2005 to 2023, he was an Independent Director at Seagen Inc. He also held positions as a Director at Phenomix Corp. and CoTherix, Inc. In 2018, he served as an Independent Director at Aerie Pharmaceuticals, Inc. and as a Director from 2012 to 2015. He was the Lead Independent Director at Hyperion Therapeutics, Inc. from 2010 to 2014. Additionally, he served as a Director at GW Pharmaceuticals Ltd. from 2020 to 2021, Argos Therapeutics, Inc. from 2012 to 2014, and PDL BioPharma, Inc. from 2014 to 2020. He held the position of Chief Financial Officer & Senior Vice President at Celgene Corp. from 2006 to 2010 and at Scios, Inc. from 2000 to 2004. He was also the Chief Financial Officer & Vice President-Finance at Cardiac Pathways Corp. from 1993 to 1998. He worked as an Audit Partner at Ernst & Young LLP and as a Principal at Strategic Consulting Group, Inc. He holds an MBA from Golden Gate University and an undergraduate degree from Loyola University of Chicago. |
| Barbara K. Finck |
Barbara K. Finck is an Independent Director at Forte Biosciences, Inc. since 2022 and a Director at Comera Life Sciences, Inc. since 2001. She previously worked as a Medical Director at Immunex Corp. from 1996 to 2001, a Director at Comera Life Sciences Holdings, Inc., a Manager-Clinical Program at ALZA Corp. from 1994 to 1996, a Vice President-Clinical Development at Protein Design Labs, Inc. from 2003 to 2006, a Chief Medical Officer & Senior VP-Research at Osprey Pharmaceuticals USA, Inc. from 2007 to 2010, a Vice President-Clinical Development at EOS Biotechnology, Inc. from 2001 to 2003, and an Assistant Professor at The University of California, San Francisco from 1992 to 1994. She also held positions at PDL BioPharma, Inc., Osprey Pharmaceuticals Ltd., NKT Therapeutics, Inc., and Coherus BioSciences, Inc. Dr. Finck completed her undergraduate degree at the University of California, Santa Barbara and obtained her doctorate from UCSF School of Medicine. |
| Stephen K. Doberstein |
Stephen K. Doberstein is currently serving as an Independent Director at Forte Biosciences, Inc. since 2022 and as a Principal at Kahiliholo Consulting LLC since 2020. Previously, he held positions such as Director-Pharmaceutical Target Research at Exelixis, Inc. from 1997 to 2000, Independent Director at Dicerna Pharmaceuticals, Inc. from 2020 to 2021, Engineer at EIDP, Inc., Chief Scientific Fellow & Senior Vice President at Nektar Therapeutics from 2019 to 2020, Vice President-Research at XOMA Corp., Vice President-Research at Five Prime Therapeutics, Inc. from 2004 to 2008, and Vice President-Research at Xencor, Inc. from 2001 to 2004. Dr. Doberstein obtained his undergraduate degree from the University of Delaware and his doctorate degree from The Johns Hopkins University School of Medicine. |
